AdaptHealth [AHCO] vs Boston Scientific [BSX] Detailed Stock Comparison
AdaptHealth
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: AdaptHealth wins in 7 metrics, Boston Scientific wins in 12 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AdaptHealth | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.83 | 57.93 | AdaptHealth |
| Price-to-Book Ratio | 0.76 | 6.43 | AdaptHealth |
| Debt-to-Equity Ratio | 122.33 | 53.09 | Boston Scientific |
| PEG Ratio | -0.73 | 0.40 | AdaptHealth |
| EV/EBITDA | 4.89 | 33.14 | AdaptHealth |
| Profit Margin (TTM) | 2.49% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | 7.10% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | 7.10% | 18.63% | Boston Scientific |
| Return on Equity | 5.51% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | 3.70% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $235.78M | $2.37B | Boston Scientific |
| 1-Year Return | -11.20% | 11.02% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 0.38 | 7.80 | AdaptHealth |
| Enterprise Value | $3.09B | $155.93B | Boston Scientific |
| EV/Revenue Ratio | 0.95 | 8.43 | AdaptHealth |
| Gross Profit Margin (TTM) | -9.11% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $24 | $13 | AdaptHealth |
| Earnings per Share (Diluted) | $0.54 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 1.62 | 0.61 | Boston Scientific |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
AdaptHealth vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AdaptHealth | -1.43% | 3.23% | -4.88% | -3.14% | -6.28% | -7.63% |
| Boston Scientific | -0.64% | -0.35% | -10.58% | -6.87% | 5.64% | 8.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AdaptHealth | -11.20% | -56.65% | -68.16% | -7.63% | -7.63% | -7.63% |
| Boston Scientific | 11.02% | 141.87% | 151.56% | 466.49% | 1,472.36% | 305.28% |
News Based Sentiment: AdaptHealth vs Boston Scientific
AdaptHealth
News based Sentiment: MIXED
The month of October 2025 saw a surge in institutional investment in AdaptHealth, indicating growing confidence from major players. However, this positive trend is offset by an insider sale and conflicting analyst ratings, creating a mixed investment narrative. The overall significance is high due to the substantial capital inflows.
Boston Scientific
News based Sentiment: POSITIVE
October was a largely positive month for Boston Scientific, highlighted by strong Q2 earnings, strategic acquisitions like Elutia, and continued positive analyst sentiment. While insider selling is a concern, the overall narrative points to a company well-positioned for future growth and market leadership, making it a significant month for investors.
Performance & Financial Health Analysis: AdaptHealth vs Boston Scientific
| Metric | AHCO | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.26B | $144.20B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 914,870 | 12,773,240 |
| 90 Day Avg. Volume | 1,022,170 | 10,174,867 |
| Last Close | $8.96 | $96.70 |
| 52 Week Range | $7.11 - $11.63 | $80.64 - $109.50 |
| % from 52W High | -22.96% | -11.69% |
| All-Time High | $41.58 (Feb 01, 2021) | $109.50 (Sep 09, 2025) |
| % from All-Time High | -78.45% | -11.69% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.23% |
| Quarterly Earnings Growth | -0.25% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.14% |
| Operating Margin (TTM) | 0.07% | 0.19% |
| Return on Equity (TTM) | 0.06% | 0.12% |
| Debt to Equity (MRQ) | 122.33 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $12.00 | $15.14 |
| Cash per Share (MRQ) | $0.53 | $0.36 |
| Operating Cash Flow (TTM) | $552.34M | $4.28B |
| Levered Free Cash Flow (TTM) | $235.10M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: AdaptHealth vs Boston Scientific
| Metric | AHCO | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.83 | 57.93 |
| Forward P/E | 10.69 | 34.88 |
| PEG Ratio | -0.73 | 0.40 |
| Price to Sales (TTM) | 0.38 | 7.80 |
| Price to Book (MRQ) | 0.76 | 6.43 |
| Market Capitalization | ||
| Market Capitalization | $1.26B | $144.20B |
| Enterprise Value | $3.09B | $155.93B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.95 | 8.43 |
| Enterprise to EBITDA | 4.89 | 33.14 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.61 |
| Book Value per Share (MRQ) | $12.00 | $15.14 |
Financial Statements Comparison: AdaptHealth vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AHCO | BSX |
|---|---|---|
| Revenue/Sales | $580.47M | $4.66B |
| Cost of Goods Sold | $657.44M | $1.45B |
| Gross Profit | $-76.97M | $3.21B |
| Research & Development | N/A | $443.00M |
| Operating Income (EBIT) | $23.17M | $937.00M |
| EBITDA | $117.52M | $1.23B |
| Pre-Tax Income | $-5.23M | $805.00M |
| Income Tax | $850,000 | $133.00M |
| Net Income (Profit) | $-6.08M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AHCO | BSX |
|---|---|---|
| Cash & Equivalents | $53.65M | $725.00M |
| Total Current Assets | $745.17M | $7.34B |
| Total Current Liabilities | $576.73M | $5.06B |
| Long-Term Debt | $2.04B | $10.93B |
| Total Shareholders Equity | $1.57B | $22.45B |
| Retained Earnings | $-569.39M | $3.35B |
| Property, Plant & Equipment | $1.03B | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AHCO | BSX |
|---|---|---|
| Operating Cash Flow | $95.33M | $513.00M |
| Capital Expenditures | $-95.59M | $-187.00M |
| Free Cash Flow | $-58,000 | $277.00M |
| Debt Repayment | $-28.22M | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AHCO | BSX |
|---|---|---|
| Shares Short | 10.40M | 19.02M |
| Short Ratio | 11.51 | 2.76 |
| Short % of Float | 0.10% | 0.01% |
| Average Daily Volume (10 Day) | 914,870 | 12,773,240 |
| Average Daily Volume (90 Day) | 1,022,170 | 10,174,867 |
| Shares Outstanding | 134.60M | 1.47B |
| Float Shares | 89.45M | 1.48B |
| % Held by Insiders | 0.08% | 0.00% |
| % Held by Institutions | 1.04% | 0.94% |
Dividend Analysis & Yield Comparison: AdaptHealth vs Boston Scientific
| Metric | AHCO | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |